Full View

Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection

S Segal-Maurer, E DeJesus, HJ Stellbrink… - … England Journal of …, 2022 - Mass Medical Soc
Background Patients with multidrug-resistant human immunodeficiency virus type 1 (HIV-1)
infection have limited treatment options. Lenacapavir is a first-in-class capsid inhibitor that …
被引用次数：137 相关文章

Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.

S Segal-Maurer, E DeJesus, HJ Stellbrink… - The New England …, 2022 - europepmc.org
Background Patients with multidrug-resistant human immunodeficiency virus type 1 (HIV-1)
infection have limited treatment options. Lenacapavir is a first-in-class capsid inhibitor that …

Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection

S Segal-Maurer, E DeJesus… - The New England …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Patients with multidrug-resistant human immunodeficiency virus type 1 (HIV-1)
infection have limited treatment options. Lenacapavir is a first-in-class capsid inhibitor that …

Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection.

S Segal-Maurer, E Dejesus, HJ Stellbrink, A Castagna… - 2022 - cabidigitallibrary.org
Background: Patients with multidrug-resistant human immunodeficiency virus type 1 (HIV-1)
infection have limited treatment options. Lenacapavir is a first-in-class capsid inhibitor that …

Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection

S Segal-Maurer, E Dejesus, HJ Stellbrink… - NEW ENGLAND …, 2022 - iris.unisr.it
BACKGROUND: Patients with multidrug-resistant human immunodeficiency virus type 1
(HIV-1) infection have limited treatment options. Lenacapavir is a first-in-class capsid …